Global Stock News

TScan Therapeutics, Inc. Announces Pricing of Initial Public Offering

Article feature image

TScan Therapeutics, Inc. Announces Pricing of Initial Public Offering

WALTHAM, Mass., July 15, 2021 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (TScan), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced…

Click here to view the original article.

Share this article

Scroll to Top